PressDecember 6, 2024 MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy
PressDecember 2, 2024 Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management
PressNovember 25, 2024 Revitalist Releases Benefits Program Giving Access To All for Ketamine Therapies Changing the Narrative of Mental Health to Risk Mitigation
PressNovember 20, 2024 Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing
PressNovember 19, 2024 Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™
PressNovember 18, 2024 MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer
PressNovember 18, 2024 Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
PressNovember 18, 2024 Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders
PressNovember 15, 2024 Numinus Wellness Announces Sale of Clinics and Unique Data Partnership to Increase Access to Mental Health Care
PressNovember 15, 2024 Filament Health Announces Third Quarter 2024 Financial Results and Operational Highlights
PressNovember 14, 2024 Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
PressNovember 14, 2024 PharmAla Reaches Agreement in Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License
PressNovember 13, 2024 Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq Form 6 K
PressNovember 13, 2024 Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
PressNovember 13, 2024 atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
PressNovember 12, 2024 Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke
PressOctober 31, 2024 PharmaDrug’s Sairiyo Therapeutics Announces Successful Completion of Stability Study of PD-001 (Patented Reformulated Cepharanthine) to Support Use in Phase 1 Study for Viral Infectious Diseases
PressOctober 31, 2024 Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs
